EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 532 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Veteran Avoided The Barber For 6 Years After He Left The... February 28, 2020 EMA Recommends Extension of Indications for Crizotinib September 23, 2022 ΚΑΡΚΙΝΟΣ ΗΠΑΤΟΣ December 10, 2018 Tumour-Infiltrating Clonal Haematopoiesis Increases the Risk of Recurrence or Death Among... May 7, 2025 Load more HOT NEWS 21-Month-Old Girl Celebrates After Beating Stage 4 Cancer Following Abnormal Cancer Screening Results, Multi-Level Reminders May Increase Follow-Up Tables Turned Scottish Soccer Star Who Just Announced Breast Cancer Diagnosis Scores Goal,...
